BioLineRx Announces Receipt Of Notice Of Allowance For Patent Covering BL-5010

(RTTNews) - Israel-based biopharmaceutical development company BioLineRx Ltd. (BLRX) announced the issuance of a Notice of Allowance by the United States Patent and Trademark Office or USPTO for a patent application claiming the composition of BL-5010, a novel composition for the non-surgical removal of skin lesions. When issued, this patent would remain valid until 2022, with corresponding patents already granted in Europe and Israel. A second patent application concerning the product is pending worldwide. Patents to be issued in the future based on this application would be valid until 2033.

The company's Chief Executive stated: "The novel BL-5010 formulation has already demonstrated outstanding results in a 60-patient clinical trial for seborrheic keratosis, in which a single application of BL-5010 achieved lesion removal in 96.7% of the cases, along with good to excellent cosmetic outcomes. We are now in final preparations for a pivotal CE-mark registration trial on the final product, known as BL-5010P, expected to begin by the end of this year. Success in this study should enable us to immediately apply for CE-mark registration of the product, which could be ready for the European market by the end of 2014. Our future development plans for this product include expansion to additional therapeutic indications, including actinic keratosis, a pre-cancerous skin condition. In parallel, we are also currently engaged in meaningful discussions with potential partners."